Revenue distribution by industry (estimated for 2025):

• Healthcare services: approx. 45%
• Dialysis products and services: approx. 35%
• Hospital management: approx. 15%
• Generics and infusion therapies: approx. 5%

TOP 3 markets and their percentage shares (estimated for 2025):

• USA: approx. 35%
• Germany: approx. 20%
• China: approx. 10%

Fresenius SE & Co. KGaA is a globally active healthcare company operating in several key industries. The largest share of revenue comes from healthcare services, followed by dialysis products and services provided through its subsidiary Fresenius Medical Care.

The USA is the largest market for Fresenius, attributed to the strong presence of Fresenius Medical Care and the high demand for healthcare services. Germany, as the home market, also plays a significant role, while China is gaining importance due to the growing healthcare sector and the company's strategic expansion.

Production sites of Fresenius SE & Co. KGaA:

1. Europe: Germany, Spain, Sweden
2. North America: USA, Canada
3. Asia: China, India
4. Latin America: Brazil, Mexico

Fresenius SE & Co. KGaA is a globally active healthcare company with a variety of production sites worldwide. In Europe, the main production facilities are located in Germany, where the company is headquartered, as well as in Spain and Sweden. In North America, Fresenius operates significant production plants in the USA and Canada to serve the local market.

In Asia, the company has production sites in China and India, supplying both the local and international markets. In Latin America, Brazil and Mexico are important locations for the production and distribution of Fresenius products.

This global presence enables Fresenius to efficiently respond to regional market demands and distribute its products worldwide.

Revenue Growth: 4.2% (2024) Profit Growth: 3.5% (2024)

Fresenius SE & Co. KGaA pursues a strategy aimed at diversification and innovation to secure future growth. The company focuses on expanding into emerging markets to benefit from the increasing demand for healthcare services.

Another focus is on digitization and the implementation of new technologies in their healthcare services to increase efficiency and patient satisfaction. Fresenius also invests in research and development to develop new products and services that meet the changing needs of the healthcare market.

Furthermore, Fresenius plans to strengthen its market position and explore new business areas through strategic acquisitions and partnerships. These measures are intended to make the company more resilient to market volatilities and promote long-term profitable growth.

Main raw materials/materials: Medical devices, pharmaceutical ingredients, dialysis products

Countries of origin: USA, Germany, China, India

Fresenius SE & Co. KGaA is a globally active healthcare company that operates in various fields such as dialysis, hospital infrastructure, and pharmaceuticals. The company imports a variety of raw materials and materials necessary for the production and operation of its products and services.

Medical devices and components are often imported from the USA and Germany, as these countries are leading in medical technology. Pharmaceutical ingredients, especially for the production of generics and other medications, are often sourced from India, which is a significant producer of pharmaceutical active ingredients. China is also an important supplier, especially for cost-effective medical components and materials.

These global supply chains enable Fresenius to offer high-quality products at competitive prices while accessing the latest technological developments in medical technology.

Market share in the healthcare sector: 10% (2024, estimated)
EBITDA margin: 15.2% (2024)
Research & Development (R&D) expenses: 1.2 billion euros (2024)

Fresenius SE & Co. KGaA has a significant competitive advantage in the healthcare sector, especially due to its diversified business structure, which includes hospitals, dialysis centers, and pharmaceutical products. The market share of around 10% in the healthcare sector demonstrates the company's strong presence.

The EBITDA margin of 15.2% highlights the efficiency and profitability of the company, which is considered above average compared to many competitors. This margin enables Fresenius to invest in further growth initiatives.

Another important aspect is the continuous investment in research and development. With R&D expenses of 1.2 billion euros in 2024, Fresenius demonstrates its commitment to innovation and the development of new products and services, which strengthens its competitive position in the long term.

In summary, it can be said that Fresenius possesses a solid competitive advantage through its strong market position, operational efficiency, and innovation capabilities.

Institutional investor share: approx. 40% (2025, estimated)

Insider purchases/sales: No significant transactions in the last quarter (2025, estimated)

The institutional investor share in Fresenius SE & Co. KGaA typically stands at around 40%, which is common for a company of this size and industry. These investors include pension funds, investment funds, and other large financial institutions seeking long-term investments.

In 2025, there were no significant insider transactions that could indicate a change in management's confidence in the company's future development. Such transactions are often seen as an indicator of management's assessment of the company's development.

Market Share Fresenius SE & Co. KGaA: Estimate 10% in the healthcare sector (2025)

Main Competitors and their Market Shares:

1. Roche Holding AG: 15%
2. Novartis AG: 14%
3. Sanofi S.A.: 12%
4. Pfizer Inc.: 11%
5. Fresenius SE & Co. KGaA: 10%
6. Johnson & Johnson: 9%
7. Merck & Co., Inc.: 8%
8. GlaxoSmithKline plc: 7%
9. AstraZeneca plc: 6%
10. AbbVie Inc.: 5%

Moat of Fresenius SE & Co. KGaA:

Fresenius SE & Co. KGaA has a significant moat, which consists of several factors. These include a strong market position in the field of dialysis services through Fresenius Medical Care, a diversified product range, and a global presence. These factors provide the company with a certain resilience to market fluctuations and competitive pressures.

However, compared to its competitors, Fresenius' moat is less pronounced than that of companies like Roche or Novartis, which have a broader range of patented drugs and a stronger research and development base. These companies often have a technological advantage and higher innovation capabilities, giving them a more robust moat.

In summary, Fresenius SE & Co. KGaA has a solid but not insurmountable moat. The competition has stronger protective mechanisms, especially through innovation and patents, which leave Fresenius behind in some areas.

Revenue Growth: 3.5% (2024) Profit Growth: 2.8% (2024) Debt Ratio: 1.9 (2024)

Fresenius SE & Co. KGaA recorded a moderate revenue growth of 3.5% in 2024. This shows that the company is able to increase its revenues despite a challenging market environment. The profit growth of 2.8% indicates that the company was also able to slightly improve its profitability.

The debt ratio of 1.9 is an important indicator of the company's financial stability. A value below 2.0 is generally considered acceptable and shows that Fresenius can manage its debts well in relation to its equity.

Overall, Fresenius demonstrates solid financial performance with stable growth and controlled debt. This could make the stock an attractive investment, especially for investors interested in stable and established companies. However, it is advisable to also consider future strategic initiatives and market conditions to make an informed investment decision.

Dividend yield: 3.5% (2024) Dividend history: 29 years of uninterrupted dividend payments

Fresenius SE & Co. KGaA has a long tradition of dividend payments and is known for its reliability in distribution. The company has consistently paid dividends for the past 29 years, indicating strong financial stability and a sustainable business model.

The dividend yield of 3.5% in 2024 shows that Fresenius offers its shareholders an attractive return. This reliability in dividend policy makes Fresenius a popular choice for investors seeking regular income.